Albany Molecular Research, Inc. renames two key acquisitions

18-Jan-2001

Albany Molecular Research, Inc. (NASDAQ:AMRI) today announced it has renamed two key acquisitions. Both acquisitions will no longer use their former names and will henceforth become known as Albany Molecular Research.

EnzyMed, located in Iowa City, IA, has been renamed "Albany Molecular Research, Inc. Biocatalysis Division." AMRI acquired EnzyMed in October 1999. American Advanced Organics (AAO), located in Syracuse and Cicero, NY, will become known as AMRI's "Syracuse Research Center." AMRI acquired AAO in February 2000.

"Albany Molecular Research, Inc. is one integrated business, rather than three separate but related entities," said Chairman and CEO Tom D'Ambra. "Renaming these two divisions better reflects AMRI's integrated, comprehensive and complementary services in chemistry research and development."

For example, AMRI's Biocatalysis Division utilizes expertise in a proprietary form of combinatorial biocatalysis. The technique, which uses enzymes and microbial systems to accelerate drug discovery, adds another dimension to AMRI's existing drug discovery and lead optimization efforts in custom chemical synthesis, molecular modeling and combinatorial chemistry. The technique has applications in the pharmaceutical, biotechnology and agrochemical industries.

AMRI's new "Syracuse Research Center" provides scale-up and chemical development services of active pharmaceutical ingredients and intermediates under extremely tight deadlines. The division complements AMRI's existing capabilities in process research and development.

https://www.chemeurope.com/en/news/831/albany-molecular-research-inc-renames-two-key-acquisitions.html